AU2001252032B2 - Fluorescent compounds - Google Patents
Fluorescent compounds Download PDFInfo
- Publication number
- AU2001252032B2 AU2001252032B2 AU2001252032A AU2001252032A AU2001252032B2 AU 2001252032 B2 AU2001252032 B2 AU 2001252032B2 AU 2001252032 A AU2001252032 A AU 2001252032A AU 2001252032 A AU2001252032 A AU 2001252032A AU 2001252032 B2 AU2001252032 B2 AU 2001252032B2
- Authority
- AU
- Australia
- Prior art keywords
- ring
- double bond
- compound
- formula
- rings
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title claims description 139
- 238000000034 method Methods 0.000 claims description 39
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 230000005284 excitation Effects 0.000 claims description 26
- 239000007850 fluorescent dye Substances 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 15
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 15
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- 238000010186 staining Methods 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical group 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 230000002538 fungal effect Effects 0.000 claims description 7
- 238000002372 labelling Methods 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 4
- 101150065749 Churc1 gene Proteins 0.000 claims description 4
- 102100038239 Protein Churchill Human genes 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 238000000386 microscopy Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 2
- 238000004163 cytometry Methods 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 238000004611 spectroscopical analysis Methods 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 11
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 150000004982 aromatic amines Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 150000004668 long chain fatty acids Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000003460 sulfonic acids Chemical class 0.000 claims 1
- 150000002894 organic compounds Chemical class 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000000499 gel Substances 0.000 description 16
- 239000000284 extract Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000975 dye Substances 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000233866 Fungi Species 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- -1 antibodies Proteins 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000003595 spectral effect Effects 0.000 description 6
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HNVJWWBKFFDQAA-NRKPLWJESA-N [(7r,8r,8ar)-7-hydroxy-7-methyl-6-oxo-3-[(e)-prop-1-enyl]-8,8a-dihydro-1h-isochromen-8-yl] 2,4-dihydroxy-6-methylbenzoate Chemical compound O([C@H]1[C@@](C)(O)C(=O)C=C2C=C(OC[C@@H]21)/C=C/C)C(=O)C1=C(C)C=C(O)C=C1O HNVJWWBKFFDQAA-NRKPLWJESA-N 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
- 229960005542 ethidium bromide Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000001551 total correlation spectroscopy Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 238000001911 insensitive nuclei enhancement by polarisation transfer Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 230000028070 sporulation Effects 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 238000004324 time-proportional phase incrementation Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 1
- 238000012584 2D NMR experiment Methods 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 238000000292 Malcolm Levitt pulse sequence Methods 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000078006 Shaka Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 description 1
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
WO 01/81351 PCT/AU01/00472 FLUORESCENT COMPOUNDS Technical Field This invention relates generally to novel fluorescent compounds and to compounds which can function as fluorescent dyes, methods of isolating such compounds from microorganisms and uses of such compounds in scientific applications.
Background Art Compounds that fluoresce have many uses and are known to be particularly suitable for biological applications where fluorescence is required for the detection of whole cells, cellular components, and cellular functions. For example, many diagnostic and analytical techniques require the samples to be fluorescently tagged so that they can be detected. This is achieved by using fluorescent dyes or probes which interact with a wide variety of materials such as cells, tissues, proteins, antibodies, enzymes, drugs, hormones, lipids, nucleotides, nucleic acids, carbohydrates, or natural or synthetic polymers to make fluorescent conjugates.
With synthetic fluorescent probes, ligands are frequently used to confer a specificity for a biochemical reaction that is to be observed and the fluorescent dye provides the means of detection or quantification of the interaction. These applications include, among others, the detection of proteins for example in gels or aqueous solution), cell tracking, the detection of proteins via fluorescently labelled antibodies, the assessment of enzymatic activity, the staining of nucleic acids.
Long wavelength absorbance usually increases the utility of a fluorescent probe since it reduces the interference from cellular autofluorescence and reduces the cytotoxic effect of the fluorophore in combination with light. Although lasers are particularly useful as a concentrated light source for the excitation of fluorescence, at present the output of lasers is restricted to particular wavelengths of light. Compounds whose excitation spectra coincide with laser output are therefore of high utility. The argon laser is the most common light source for excitation of fluorescence, and has principal outputs, light at 488 nm and 514 nm.
Fluorescent compounds that are excited by either of these wavelengths are therefore of particular utility. Alternatively, excitation of fluorescence can be achieved using solid state light sources such as Light emitting diodes.
WO 01/81351 PCT/AU01/00472 2 Fluorescent compounds excited by the light emitted from these alternative sources are also of particular utility.
Red fluorescent compounds are used extensively in many fields of biological study. Many of these, including Texas red, Tetramethyl rhodamine-isothiocyanate or red emitting BODIPY dyes require excitation at green wavelengths such as 542 nm. This limits their use in many applications, especially those where the argon-ion laser is used for excitation.
Compounds such as ethidium bromide, can be excited with light from the argon-ion laser (520 nm band), but are not generally suitable for tagging of organic molecules other than nucleic acids. Other compounds such as phycoerythrin, can be excited using the argon-ion laser (488 nm) and does emit in the orange/red wavelengths. Phycoerythrin, however, has poor stability and a high molecular weight making it unsuitable for many applications such as cell tracking, labelling of nucleic acids or staining proteins.
For staining of proteins, there are a number of methods available.
These methods can utilise non-fluorescent compounds, or fluorescent compounds. The most commonly used method utilises Coomassie blue which is non-fluorescent, can require the use of large amounts of organic solvents and is time consuming. Other fluorescence-based protein-detection methods are available which are potentially more sensitive than nonfluorescent methods. However, these methods are in general much more expensive than non-fluorescent methods which limits their widespread use.
Therefore, compounds that combine useful spectral characteristics, and relatively high sensitivity will be of particular utility.
There are several methods for the quantification of protein in solution.
These methods are based on a range of techniques, and include methods where dyes bind to soluble proteins. These dyes can be either nonfluorescent or fluorescent compounds. Fluorescent dye-based methods are often more sensitive than the non-fluorescent dyes, and allow for the determination of protein concentration over a wide range of concentrations, Compounds that combine useful spectral characteristics with an ability to bind proteins will be of particular utility.
In enzymatic studies, there is widespread use of fluorescent compounds for the detection of particular enzymatic activities. For example, fluorescein di-P-D-galactopyranoside (FDG) is a non-fluorescent compound PCT/AU01/00472 Received 31 July 2002 3 fluorescent. The cleavage of the FDG compound can be monitored by the increase in fluorescence in the solution, and thus allows sensitive quantification of enzymatic activity. At present, only a limited number of fluorophores are suitable for this procedure. Therefore, novel fluorescent compounds that can be conjugated to a variety of substrates will be of utility.
For dual colour staining, there is a very limited choice of low molecular weight fluorophores. The predominant green fluorophore is fluorescein, which strongly absorbs light from the 488 nm band of the argon ion laser, and re-emits at 518 nm. At present there are few compatible red or orange fluorophores that are of low molecular weight and are excited by the 488 nm or 514 nm bands of the argon ion laser. Therefore, low molecular weight compounds that are excited by argon ion lasers and emit at wavelengths greater than 600 nm will be of utility, particularly if there is minimal spectral overlap with fluorescein, The present inventors have isolated new compounds derived from a fungus that are capable of combining readily with a range of organic molecules to produce fluorescent complexes.
Disclosure of Invention In a first aspect of the invention, there is provided a compound according to formula
R"
A B C 0 4
(I)
wherein: each of R, R' and R" is a hydrogen atom, halogen atom or a straight or branched chain C.2o alkyl, alkenyl or alkynyl group optionally substituted with one or more halogen, hydroxy and/or oxo group; rings A, B and C optionally include one or more double bonds; rings B and C are optionally substituted with one or more halogen atoms; and AMENDED SHEET IPF.-4AU PCT/AU01/00472 Received 31 July 2002 4 the compound is capable of interacting with an organic compound and when interacting with the organic compound, the compound emits fluorescence after excitation at a broad range of wavelengths. Preferably, the compound is excited at wavelengths in the range of 300-560 nm, more preferably, 380-530 nm and even more preferably, UV wavelengths and/or blue wavelengths. Preferably the compound emits in the wavelengths of 460 to 700 nm. More preferably its emission peak is centered around 530 nm when interacting with an organic compound such as sodium dodecyl sulphate and centered around 605 nm when interacting with a biomolecule such as a protein or cell.
Preferably, the first aspect of the invention provides a compound according to formula (Ia): 4 Preferably, the compound according to formula Ia has the stereochemistry as depicted in formula (Ib):
H
Preferably, R is a straight or branched chain C1 2 0 conjugated alkenyl group optionally substituted with hydroxy and oxo groups; R' is a straight or AMNDED SHEET
IPENAU
PCT/AU01/00472 Received 31 July 2002 branched chain CG 1 .2 alkyl group optionally substituted with a hydroxy group and R" is a straight or branched chain C.- 20 alkyl group.
More preferably, R=-C(OH)CHC(O)(CH)BCH3,
R'=-CH
2 OH and R"=Me such that the present invention according to the first and second aspects consists in the compound 5,6-dihydro-3-[(1Z, 4E, 6E, 8E)-1-hydroxy-3-oxo- 1,4,6,8-decatetraenyl]-6-hydroxymethyl-9a-methyl-2H-furo[3,2g][2]benzopyran-2-9(9aH)-dione according to formula (Ic): 36
OH
4 5
H
O OH
H
(Ic) In a second aspect, the present invention consists in a compound according to formula wherein each of R, R' and R" is a hydrogen atom, halogen atom or a straight or branched chain C1 20 alkyl, alkenyl or alkynyl group optionally substituted with one or more halogen, hydroxy and/or oxo groups; ring A, B and C are optionally substituted with one or more halogen atoms; and rings A, B and C optionally include one or more double bonds; with the proviso that: R -C(OH)CHC(O)(CH),CH(Et)(Me) when R'=-CH 2 OH, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a; (ii) R -C(OH)CHC(O)(CH),CH(Et)(Me) when R'=Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a; AMENDED
SHEET
IPSUAU
WO 01/81351 PCT/AU01/00472 6 bond between C4 and C4a; and ring C includes a double bond between C8 and C8a; (iii) R-C(OH)CHC(O)(CH),C(Et)(Me) when R'=Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (iv) R#-C(0)(CH),Me when R'=-n-propyl, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; R#-C(O)(CH),Me when R'=-n-propyl, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (vi) R-C(O)(CH),Me when 2 Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (vii) R -C(O)(CH),Me when R'=-(CHlMe, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (viii) R -(CH),C(Me)CHC(Me)(Et) when R"=Me, C4=C1, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (ix) R -(CH)zC(Me)CHC(Me)(Et) when R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; R -(CH) 2 C(Me)CH-i-Pr when R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xi) R=-C(O)(CH),Me when R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond PCT/AUO 1/00472 Received 31 July 2002 7 (xii) R#-C(O)(CH) 4 Me when R'=-n-propyl, R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6; (xiii) R#-C(O)(CH) 4 Me when R'=-n-propyl, R"=Me, ring A, B and C do not include double bonds; (xiv) R#-C(O)(CH),Me when R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6; (xv) R#-C(O)(CH) 4 Me when R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6; (xvi) R#-C(O)(CH) 4 Me when 2 Me, R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6, including tautomers thereof.
In a third aspect, the present invention consists in a compound according to formula wherein each of R, R' and R" is a hydrogen atom, halogen atom or a straight or branched chain C 1 2 alkyl, alkenyl or alkynyl group optionally substituted with one or more halogen, hydroxy and/or oxo groups; ring A, B and C are optionally substituted with one or more halogen atoms; and rings A, B and C optionally include one or more double bonds; with the proviso that: R#-C(OH)CHC(O)(CH),CH(Et)(Me) when R'=-CH 2 OH, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a; (ii) R -C(OH)CHC(O)(CH) 6 CH(Et)(Me) when R'=Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a; (iii) R#-C(OH)CHC(O)(CH),CH(Et)(Me) when R'=Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; AMIEDED SHEET
IPEA/AU
WO 01/81351 PCT/AU01/00472 8 utility as fluorescent dyes for the staining of biomolecules or organic compounds.
None of the prior art known to the applicant teaches or suggests that a compound of the structure described in formula would be fluorescent, nor suggests that it would be suitable for use in the fluorescent staining of bio-molecules or organic compounds. There are accordingly unexpected and advantageous properties associated with this compound including sensitive detection of proteins in gels, cell tracking and dual colour staining.
The present inventors have unexpectedly found that compounds according to formula are not fluorescent in aqueous solution, but are capable of interacting with organic compounds to produce an intensely fluorescent stain. In a preferred embodiment, the compounds according to formula of the invention are used in the detection and tagging of organic molecules.
Preferably, the compound according to formula when bound to an organic molecule emits fluorescence after excitation at blue wavelengths..
More preferably, the compounds according to formula are excited by light in the absorbance range 300-560 nm, In a preferred embodiment, a compound according to formula interacts with proteins to produce a fluorescent complex that can be excited by light generated by standard UV transilluminators (307 nm), Upon excitation, the fluorescent complex emits light over a wide range of wavelengths allowing the protein complexes to be detected. The excitation wavelength of the protein/dye complex includes that of ethidium bromide complexed with DNA (Absorption maximum 518 nm, Emission maxima 605 nm). This is of particular utility because it allows the same equipment to be used to detect both DNA and protein in gels. The broad range of excitation wavelengths allows the compound to be excited strongly by 488 nm and 514 nm bands of the argon ion laser, as well as absorb light emitted from diode light sources such as those the emit at around 400 nm In another preferred embodiment, a fluorescent form of the compound according to formula is capable of strongly absorbing light from the 488 nm output of the argon-ion laser, and to re-emit the light at wavelengths longer than 600 nm.
In another preferred embodiment, the compound according to formula I is included in a composition, along with an analytically acceptable carrier, PCT/AU01/00472 Received 31 July 2002 9 (xiii) RG-C(O)(CH,) 4 Me when R'=-n-propyl, R"=Me, ring A, B and C do not include double bonds; (xiv) when R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6; (xv) R-C(O)(CH 2 4 Me when R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6; (xvi) R#-C(O)(CH)4Me when R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6, including tautomers thereof.
In a fourth aspect, the present invention consists in a compound according to formula wherein each of R, R' and R" is a hydrogen atom, halogen atom or a straight or branched chain C.
20 alkyl, alkenyl or alkynyl group optionally substituted with one or more halogen, hydroxy and/or oxo groups; ring A, B and C are optionally substituted with one or more halogen atoms; and rings A, B and C optionally include one or more double bonds; with the proviso that: R -C(OH)CHC(O)(CH])CH(Et)(Me) when R'=-CHzOH, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a; (ii) R#-C(OH)CHC(O)(CH),CH(Et)(Me) when R'=Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a; (iii) R#-C(OH)CHC(O)(CH),CH(Et)(Me) when R'=Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (iv) R:-C(O)(CH) 4 Me when R'=-n-propyl, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; AMENDED
SHEET
IPFVAV
PCT/AU01/00472 Received 22 March 2002 R-C(O)(CH),Me when R'=-n-propyl, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (vi) R#-C(O)(CH)sMe when R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (vii) R#-C(O)(CH),Me when R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (viii) R#-(CH) 2 C(Me)CHC(Me)(Et) when R"=Me, C4=C1, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (ix) R#-(CH),C(Me)CHC(Me)(Et) when R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6;
R#-(CH)
2 C(Me)CH-i-propyl when R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xi) R#-C(O)(CH) 4 Me when 2 Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xii) R -C(O)(CH) 4 Me when R'=-n-propyl, R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6; (xiii) R -C(O)(CH) 4 Me when R'=-n-propyl, R"=Me, ring A, B and C do not include double bonds; (xiv) R#-C(O)(CH),Me when 2 Me, R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6; AMENDED SHEET tPIVAU PCT/AU01/00472 Received 22 March 2002 11 (xv) R -C(O)(CH) 4 Me when R'=-C(CH 2 R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6; (xvi) R-C(O)(CH) 4 Me when R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6; (xvii) R#-C(O)(CH2)4Me when R'=-n-propyl, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xviii) when R'=-n-propyl, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xix) R -C(O)(CH2) 5 Me when R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xx) R#-C(O)(CH2),Me when 2 Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xxi) R#-Ac when R'=-(CH),C(Me)CHCH(Me)(Et), R"=Me, C4=C1, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xxii) R -Ac when 2 C(Me)CHCH(Me)(Et), R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xxiii) R -Ac when 2 C(Me)CH-i-propyl, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xxiv) R7-C(O)(CH), 4 Me when 2 Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond AMENDED SHEET
IPEA/AU
PCT/AU01/00472 Received 31 July 2002 12 between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xxv) 4 Me when R'=-n-propyl, R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6; (xxvi) R 4 Me when R'=-n-propyl, R"=Me, ring A, B and C do not include double bonds; (xxvii) when 2 Me, R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6; (xxviii) R-C(O)(CH,)4Me when R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6; (xxix)R#-C(O)(CH,)4Me when 2 Me, R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6, including tautomers thereof.
Preferably, the compound according to second, third and fourth aspect of the invention is in accordance with formula (Ia) and more preferably, has the stereochemistry as depicted in formula (Ib).
Even more preferably, R=-C(OH)CHC(O)(CH),CH 3
R'=-CH
2 OH and R"=Me such that the present invention according to the second, third and fourth aspect consists in the compound 5,6-dihydro-3-[(1Z, 4E, 6E, 8E)-1hydroxy-3-oxo-l,4,6,8-decatetraenyl]-6-hydroxymethyl-9a-methyl-2Hfuro[3,2-g][2]benzopyran-2-9(9aH)-dione acccording to formula (Ic).
It will be appreciated that the compound according to formula includes all corresponding tautomeric structures, Chemically, the compounds of formula such as 5,6-dihydro-3- 4E, 6E, 8E)-l-hydroxy-3-oxo-1,4,6,8-decatetraenyl]-6-hydroxymethyl-9amethyl-2H-furo[3,2-g][2]benzopyran-2-9(9aH)-dione, are members of the azaphilone family. The azaphilone compounds are produced by a variety of fungi, and have been investigated for their antibiotic functions, their ability to inhibit enzymatic function, and their role as colouring agents in food.
The azaphilone nucleus has also been found in the pigments produced by Monascus spp. The pigments containing the common azaphilone core include dihydro-monascin and monascorubin. There is no record of their AMENDED SHEET
IPSMAU
PCT/AU01/00472 Received 22 March 2002 13 utility as fluorescent dyes for the staining of biomolecules or organic compounds.
None of the prior art known to the applicants teaches or suggests that a compound of the structure described in formula would be fluorescent, nor suggests that it would be suitable for use in the fluorescent staining of bio-molecules or organic compounds. There are accordingly unexpected and advantageous properties associated with this compound including sensitive detection of proteins in gels, cell tracking and dual colour staining.
The present inventors have unexpectedly found that compounds according to formula are not fluorescent in aqueous solution, but are capable of interacting with organic compounds to produce an intensely fluorescent stain. In a preferred embodiment, the compounds according to formula of the invention are used in the detection and tagging of organic molecules.
Preferably, the compound according to formula when bound to an organic molecule emits fluorescence after excitation at blue wavelengths.
More preferably, the compounds according to formula are excited by light in the absorbance range 300-560 nm.
In a preferred embodiment, a compound according to formula interacts with proteins to produce a fluorescent complex that can be excited by light generated by standard UV transilluminators (307 nm). Upon excitation, the fluorescent complex emits light over a wide range of wavelengths allowing the protein complexes to be detected. The excitation wavelength of the protein/dye complex includes that of ethidium bromide complexed with DNA (Absorption maximum 518 nm, Emission maxima 605 nm). This is of particular utility because it allows the same equipment to be used to detect both DNA and protein in gels. The broad range of excitation wavelengths allows the compound to be excited strongly by 488 nm and 514 nm bands of the argon ion laser, as well as absorb light emitted from diode light sources such as those the emit at around 400 nm In another preferred embodiment, a fluorescent form of the compound according to formula is capable of strongly absorbing light from the 488 nm output of the argon-ion laser, and to re-emit the light at wavelengths longer than 600 nm.
In another preferred embodiment, the compound according to formula is included in a composition, along with an analytically acceptable carrier, AMENDED SHEET tPF /AU~ PCT/AU01/00472 Received 22 March 2002 14 and may be used in combination with a fluorochrome such as fluorescein in dual staining applications. Such a fluorochrome may be included in the composition or separately used.
The compound according to formula may be produced by a fungal species. Preferably, the fungal species is the strain deposited at the Australian Government Analytical Laboratories (AGAL) on 15 January 1998 identified by Accession Number NM98/00507.
The methods for purification, isolation, as well of the structure of the novel fluorophore 5,6-dihydro-3-[(1Z, 4E, 6E, 8E)-l-hydroxy-3-oxo-1,4,6,8decatetraenyl]-6-hydroxymethyl-9a-methyl-2H-furo[3,2-g][2]benzopyran-2- 9(9aH)-dione and related compounds have not previously been described.
The binding of the compound according to formula to organic molecules may involve direct chemical or physical binding or may be achieved by the use of "linking molecules" known to the art. Organic molecules which may be bound by the compound of the invention when used as a fluorescent dye include, for example, proteins, peptides, sugars, nucleic acids, antibodies, cell surface biomolecules, detergents and cells.
Due to the compound's fluorescent and organic compound-binding characteristics, it will be appreciated that the compound will have use in any application where detection of a fluorescent dye attached to an organic compound is required.
In a fifth aspect, the present invention consists in a process of producing a compound according to the first, second, third and fourth aspect of the invention, the process comprising culturing a fungal species under conditions such that the fungal species produces the compound; and separating the compound from the culture.
The compound according to formula can be used as a fluorescent dye when in a crude culture extract or when purified by extraction and separation techniques.
It has been found by the present inventors that after inoculation and incubation of the strain identified by AGAL Acession Number NM98/00507 on the growth medium, a compound which is suitable as a fluorescent dye is produced by the fungus.
It will be appreciated that it should be possible to produce compounds according to formula of the first, second, third and fourth aspect of the present invention by using techniques other than from the supernatant of a AMENDED SHEET
IPEA/AU
PCT/AU01/00472 Received 22 March 2002 suitable fungal culture. For example, if the fungus produces a "pre-cursor", then it will be possible to modify that pre-cursor to its fluorescent form by chemical, physical or enzymatic means. The knowledge that such compounds can be obtained from microorganisms should allow the discovery and production of other compounds suitable for use as fluorescent dyes belonging to the same family or quite distinct compounds with useful characteristics. The compound according to formula may also be produced synthetically by direct chemical synthesis, or by modification of intermediate(s) in the biosynthetic pathway used by the fungi.
The compound according to formula of the present invention may also be produced synthetically by chemical means. The knowledge that a new fluorescent compound is produced by fungi may lead to other means of producing the compound apart from culturing the fungi under the required conditions.
The compound according to formula of the present invention has the distinct advantage that it binds to cells and other organic molecules in its fluorescent form so can be used as a means to track the cells or the other organic molecules when labelled with the compound.
In a sixth aspect, the present invention consists in use of the compound according to the first and, second, third and fourth aspect of the present invention as a fluorescent dye or marker, preferably in scientific techniques for staining, labelling and/or detecting organic molecules.
Examples of the use of the compound according to the first, second, third and fourth aspect of the present invention include but are not restricted to cell tracking dyes for microscopy, membrane fluidity dyes, conjugation with antibodies, conjugation to nucleic acids, cell surface ligand imaging dyes, conjugation to sugars, cytometric analysis, and confocal microscopy. It will be appreciated, however, that the compound would be suitable for any use where fluorescence in the red wavelengths is required, including when excited at 488 nm.
In a seventh aspect, the present invention consists in a method of fluorescent-labelling an organic compound, the method comprising causing the compound according to the first, second, third or fourth aspect of the present invention to bind to an organic compound such that the organic compound is fluorescently labelled with the compound.
AMENDED SHEET
IPEAAU
PCT/AU01/00472 Received 22 March 2002 16 Preferably, the fluorescently labelled organic compound is detected when exposed to a wide range of wavelengths, preferably wavelengths in the range of 300-560 nm.
The organic compound may include, but is not limited to, proteins, peptides, sugars, nucleic acids, antibodies, cell surface biomolecules, detergents and cells. The compound may bind directly to the organic compound due to a chemical or physical association or may bind to the organic compound via a linking molecule. If the compound is attached to a ligand specific for the organic compound, for example an antibody or lectin, then the binding of that ligand to the organic compound will cause the organic compound to be fluorescently labelled.
In an eighth aspect, the present invention consists in a method of detecting an organic compound in a sample including the organic compound, the method comprising labelling the organic compound according to the method of the seventh aspect of the present invention; and detecting the organic compound in the sample by monitoring or detecting its fluorescence.
Preferably, the labelled organic compound is detected when the sample is exposed to light from a wide range of wavelengths, preferably wavelengths in the range of 300-560 nm, more preferably blue wavelengths.
The monitoring or detecting of the fluorescence of the labelled-organic compound may be by any means known to the art. Such means include, but are not limited to, transillumination, spectroscopy microscopy and cytometry.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application.
AMENDED SHEET
IPEAVAU
PCT/AU01/00472 Received 22 March 2002 17 In order that the present invention may be more clearly understood a preferred forms will be described with reference to the following examples and accompanying drawings.
Brief Description of Drawings Figure 1 shows an NMR spectrum of 5,6-dihydro-3-[(1Z, 4E, 6E, 8E)-1hydroxy-3-oxo-1,4,6,8-decatetraenyl]-6-hydroxymethyl-9a-methyl-2Hfuro[3,2-g][2]benzopyran-2-9(9aH)-dione a fluorescent compound according to the first, second, third and fourth aspects of the invention.
Figure 2 shows an example of an emission spectra of the compound identified by Figure 1 when bound to bovine serum albumin (BSA) and propidium iodide bound to DNA. The number of moles of the purified compound used to bind to excess BSA, were equal to the number of moles of propidium iodide used to bind to excess DNA. There are two excitation bands resulting in emission at 605 nm. As seen, excitation by light at 390- 400 nm results in maximum emission of light at 605 nm.
Modes for Carrying Out the Invention Example 1: Production of Extract A.
A biologically pure culture of the micro-organism having all of the identifying characteristics of the strain identified by AGAL Accession Number NM 98/00507 was obtained.
A growth medium for the fungus, AGAL Accession Number NM 98/00507, was prepared by adding 40 g Sucrose (CSR), 5 g Yeast Extract (Difco), 10 g Peptone (Difco) and 10 g Agar (Difco) to 1 L of water. The mixture was autoclaved for 15 min at 115°C to both sterilise the medium and to dissolve the agar. The liquid was poured into culture dishes and allowed to set at room temperature. After cooling, a culture of the fungus was inoculated onto the surface of the medium, and incubated at 25°C for three days. The culture was transferred to a refrigerator and incubated at 4°C until the culture turned an intense red colour and dye production was high (usually 3 to 5 days).
Once the culture produced sufficient dye for harvesting, the culture medium, including the fungal biomass was transferred into ethanol at a ratio of one volume of culture medium to two volumes of ethanol. The dye was extracted into the ethanolic phase by incubation at 4°C and shaking for 16 hours. The liquid phase was decanted from the residual culture medium, and centrifuged at 3000 rpm for 10 min at 4 0
C.
AMENDED SHEET iPENAU PCT/AU01/00472 Received 22 March 2002 18 The clarified extract (Extract A) was either stored for use, or purified further according to one of the procedures described under examples 2 and 3.
Example 2: Purification of Extract A to produce Extract B.
The crude ethanolic extract of Extract A produced according to the method described in example 1 was reduced in volume under high vacuum, chromatographed on cellulose powder using methanol as a solvent and applied to a sephadex LH-20 column, also eluted with methanol. Fractions were collected over 48 hours and the purple band eluting near the end was collected. This fraction was freeze dried and resuspended in a minimum volume of acetic acid) methanol and stored.
Example 3: Purification of5,6-dihydro-3-[(1Z, 4E, 6E, 8E)-l-hydroxy-3oxo-1,4,6,8-decatetraenyl]-6-hydroxymethyl-9a-methyl-2H-furo[3,2g][2]benzopyran-2-9(9aH)-dione.
Extract B produced according to the method described in example 2 was subjected to HPLC purification (Supelco C16-amide column, resolved in methanol/water, 0.05% acetic acid, then 50% acetonitrile/water, 0.05% acetic acid). The final fraction was frozen to remove water and the remaining acetonitrile was evaporated under a stream of nitrogen.
This procedure produced analytically pure, 6-dihydro-3-[(1Z, 4E, 6E, 8E)-l-hydroxy-3-oxo-1,4,6,8-decatetraenyl]-6-hydroxymethyl-9a-methyl-2Hfuro[3,2-g][2]benzopyran-2-9(9aH)-dione which was an orange solid.
Example 4: Structure determination of ,6-dihydro-3-[(1Z, 4E, 6E, 8E)-1hydroxy-3-oxo-1,4,6,8-decatetraenyl]-6-hydroxymethyl-9a-methyl-2Hfuro[3,2-g][2]benzopyran-2-9(9aH)-dione.
The compound produced according to example 3 was analysed using a combination of NMR spectroscopy and high resolution mass spectrometry to determine the structure of, 6-dihydro-3-[(1Z, 4E, 6E, 8E)-1-hydroxy-3-oxo- 1,4,6,8-decatetraenyl]-6-hydroxymethyl-9a-methyl-2H-furo[3,2g] [2]benzopyran-2-9(9aH)-dione.
Nuclear magnetic resonance spectroscopy.
The NMR sample was prepared by dissolving the HPLC purified compound obtained from Example 3 mg) in CDC1, (0.5 mL; 99.96 atom%, Aldrich) and filtering it into an NMR tube (PP527, Wilmald). The sample was degassed and equilibrated under an atmosphere of nitrogen.
The NMR data were acquired on a Bruker DRX600 (600 MHz) NMR spectrometer at 27°C and processed using xwinNMR (version 2.6; Bruker).
AMENDED SHEET
PFAAV
PCT/AU01/00472 Received 22 March 2002 19 All 2D NMR experiments were run with quadrature detection with an 'H spectral width of 6009 Hz and a recycle delay of 2 s. Chemical shifts were referenced to the residual CHCl (6H 7.26 ppm; 5C 77.01 ppm). High power 1H 7r/2 pulses were determined to be 9.5 ms and low power (for MLEV spin lock) at 25.15 ms. "C high power 7/2 pulse was 10.5 ms and a low power pulse of 65 ms was used for GARP decoupling. Gradient pulses were delivered along the z-axis using a 100 step sine program.
Data for 1D experiments were acquired using 32 K real points and zero filled to 64 K and then Gaussian multiplied for resolution enhancement.
Carbon hydrogen correlation (HSQC) was achieved via a sensitivity enhanced double INEPT transfer using echo/antiecho-TPPI gradient selection (Palmer, A. III, Cavanagh, and Wright, P. (1991) J. Magn. Reson. 93, 151-70; Schleucher, Schwendinger, Sattler, and Schmidt, P. (1994) J, Biomol. NMR 4, 301-6; Kay, L. Keifer, and Saarinen, T. (1992) J. Am.
Chem. Soc. 114(26), 10663-5). 2K data points were collected in t2 (128 scans per increment) with a 1.3 s recycle delay with decoupling during acquisition.
In tl, 512 increments were used (10-170 ppm) and the INEPT sequence was optimized for a X-H coupling of 145 Hz. A gradient ratio of 80:20.1 was used to select echo/antiecho-TPPI phase sensitivity.
One dimensional ROESY spectra were measured using a selective Gaussian pulse on the proton of interest (Kessler, H. Oschkinat, C.
Griesinger W. Bermel, (1986) J. Magn. Reson. 70, 106; Stonehouse, P.
Adell, J. Keeler A.J. Shaka, (1994) J. Am. Chem. Soc. 116, 6037; Stott, J.
Stonehouse, J. Keeler, T.L. Hwang A.J. Shaka, (1995) J. Am. Chem. Soc. 117, 4199 4200). A 1000 step Gaussian program (60 ms, 64.6 dB) was used to achieve a pulse. A mixing time of 100 ms (13 dB) was used for a continuos wave spin lock. Gradient selection was achieved with a gradient along the z-axis. 10K transients were accumulated over 6009 Hz.
ROE enhancements were measured as a percentage of the irradiated peak and not compensated for offset from the carrier frequency.
Two dimensional homonuclear Hartman-Hahn transfer spectra (TOCSY) were measured using the MLEV17 (Bax, Davis, D. G. (1985) J.
Magn. Reson. 63(1), 207-13) pulse sequence flanked with 2 ms low power trim pulses. Sine bell shifted (900) apodisation was used in the processing of both dimensions.
AMENDED SHEET IP EAM PCT/AU01/00472 Received 22 March 2002 2D 'H-"3C correlation via heteronuclear zero and double quantum coherence optimized for long range couplings (HMBC) with low-pass J-filter (145Hz) to suppress one-bond correlations (Bax, M.F. Summers, (1986) J. Am. Chem. Soc. 108, 2093 2094) was acquired with no decoupling during acquisition time and using gradient pulses (50:30:40.1) for selection. The delay for evolution of long range couplings was optimized for couplings of 10, 5 and 2Hz in separate experiments. A spectral width of 210ppm was used in Fl and the final spectrum magnitude calculated to destroy phase information.
'H NMR (600MHz, CDCl,) 5 1.75, s, C9a-Me; 1.84, dd, J 6.7, 1.1 Hz, C9'- Me; 2.80, dd, J 17.2, 3.6 Hz, H5a; 2.89, ddd, J 17.1, 11.5, 1.9 Hz, H53; 3.85, dd, J 12.2, 5.5 Hz, C6CHOH; 3.97, dd, J 12.2, 3.4 Hz, C6CH0OH; 4.39, m, H6; 5.97, m, H9'; 6.10, d, J 15.1 Hz, H4', 6.19, ddd, J 15.1, 10.6, 1.6 Hz, H8'; 6.25, dd, J 14.6, 11.2 Hz, H6'; 6.58, dd, J 14.5, 10.5 Hz, H7'; 6.79, s, H2'; 7.16, bs, H4, 7.32, dd, J 15.2, 11.2 Hz, H5'; 7.85, s, H8.
13C NMR (125MHz, CDC1 3 6 18.8, C9'-Me; 28.0, C9a-Me; 29.3, C5; 63.4, C6-CHOH; 79.0, C6; 86.2, C9a; 101.0, C2'; 112.2, C8a; 113.4, C4; 115.3, C3; 126.5, C4'; 128.6, C6'; 131.7, C8'; 136.0, C9'; 140.9, C4a; 142.0, C7'; 142.6, 159.0, C8; 168.2, C2/C3a; 177.7, C1'; 185.0, C3'; 190.0, C9.
Heteronuclear single quantum coherence (HSQC) was used to correlate and assign all protons to protonated carbons. In addition, each spin system was characterised by running a series of total correlation spectroscopy (TOCSY) experiments with mixing times of 8 msec, 20 msec, 100 msec. The shortest mixing time gave correlations to only the directly coupled protons whereas the longest mixing time identified the entire spin system and gave information about very small long range couplings which were valuable for assigning the positions of the many (apparently) uncoupled protons.
Thorough space connectivities were achieved by a series of one dimensional selective rotating frame correlation spectroscopy (ROESY) experiments.
Selective excitation was achieved by a low power Gaussian 90 degree pulse and using gradient section to observe only ROE's free of TOCSY transfers. A mixing time of 100 msec was found to be optimal. Long range heteronuclear multiple quantum coherence (HMBC) spectra with mixing times of 25, 100 and 250 msec was found to be essential to assign all non-protonated carbons. Even after this, C2 was found not to correlate with any protons and was coincident with C3a at 168.2 ppm.
AMENDED SHEET
IPEAA
PCT/AU01/00472 Received 22 March 2002 21 From the spectral data, several tricyclic skeletons were theoretically possible but one (6-dihydro-3-[(1Z, 4E, 6E, 8E)-l-hydroxy-3-oxo-1,4,6,8decatetraenyl]-6-hydroxymethyl-9a-methyl-2H-furo[3,2-g] [2]benzopyran-2- 9(9aH)-dione), fitted the available data exactly.
Mass Spectrometry The compound produced according to Example 3 was subjected to high resolution mass spectrometry to determine that the molecular formula of the compound was C 23 H,0 7 Mass spectrum (ESI, positive ion) m/e 411 (M+H 317 249 163 121 (100), 93 Negative ion ESI-FTICR Found: M H 409.1304, C 23 Hz,0 7 requires 409.1293; found: 247.0617, C1 3
H
1 zO 5 requires 247.0685.
UV-Visible and Infrared Spectrometry (MeOH) 432, 555 nm, a 10000, 4000. (alkaline MeOH) 432 nm, e 16000. (acidic MeOH) 390, 560 nm, 8 6000, 10000.
vm. (neat) 3400 2925, 2854, 1744, 1712, 1589, 1259, 1010 cm' 1 Example 5: Protein gel staining using Extract A.
A protein gel was prepared according to any one of a number of standard protocols. For example, an SDS page gel was prepared according to the protocol of Laemmli 1970, Nature, 227:680-685). After electrophoresis was completed, the gel was removed from the electrophoresis apparatus. The gel was fixed in a container containing 100 mL of a staining solution composed of 90 mL water, 10 mL glycerol and 5 mL of Extract A.
The gel and staining solution were incubated with gentle shaking for minutes. After the 90 minute staining procedure, the solution was removed and the gel briefly washed three times in water. After these brief washes, the gel was placed in 100 mL of 10% glycerol in water and incubated with shaking for a further 30 min.
To visualise the proteins in the gel, the gel was transferred to a UV transilluminator (307 nm), and photographed using polaroid 667 black and white film and a filter set designed for the detection of ethidium bromide gels (eg. Molecular probes E-7591).
Example 6: Epifluoroescence differentiation of sporulated and vegetative cells.
A micro-organism is cultured under conditions to promote sporulation and Extract B is used to facilitate the identification of sporulated cells within AMENDED SHEET 11Bqa e PCT/AU01/00472 Received 22 March 2002 22 a predominantly vegetative cell culture. For example, Saccharomyces cerevisiae was grown in a water based broth containing 10 g/L Glucose, 5 g/L yeast extract, and 10 g/L peptone. After a 16 hour incubation at 30°C, the cells were harvested by centrifugation and resuspended in 1 mL of water.
The 5 tL aliquots of the culture were spotted onto a semi-solid medium composed of 5% Potassium acetate, 2% Agar and water. The cultures were incubated at 220C for 4 days to allow sporulation of the yeast cells. The sporulated culture was resuspended in water to a density of 1 x 10 9 cells per mL. 5 jiL of Extract B was added to 1 mL of the sporulated culture. To counterstain, 5 tL of a 10 mM solution (in DMSO) of 5(6)-carboxyfluorecein diacetate (CFDA), was added to the sporulated culture. After 5 minutes, the sporulated culture was harvested by centrifugation and resuspended in 1 mL of water. Examination under an epifluorescence microscope (excitation 488 nm) allowed for rapid differentiation between sporulated and vegetative cells.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
AMENDED SHEET
PEVAU
Claims (29)
1. A complex comprising a compound according to formula wherein: each of R, R' and R" is a hydrogen atom, halogen atom or a straight or branched chain Cl- 20 alkyl, alkenyl or alkynyl group optionally substituted with one or more halogen, hydroxy and/or oxo group; rings A, B and C optionally include one or more double bonds; rings B and C are optionally substituted with one or more halogen atoms, including tautomers of formula and an organic molecule, wherein the organic molecule is a nitrogen containing molecule, and wherein the compound of formula interacts with the organic molecule so as to fluoresce after excitation.
2. A complex as claimed in claim 1 comprising a compound of formula (la), including tautomers thereof: R 4
3. A complex as claimed in claim 2 comprising a compound having the stereochemistry as depicted in formula including tautomers thereof: -24- 8 (Ib) c
4. A complex as claimed in any one of claims 1 to 3 comprising a compound wherein O R is a straight or branched chain Ci. 20 conjugated alkenyl group optionally substituted N 5 with hydroxy and oxo groups; R' is a straight or branched chain C.o 20 alkyl group optionally substituted with a hydroxy group and R" is a straight or branched chain CI- 20 alkyl group, including tautomers thereof.
A complex as claimed in any one of claims 1 to 4, wherein the nitrogen containing molecule is selected from the group consisting of proteins, amino acids, peptides, nucleic acids and aliphatic or aromatic amines.
6. A complex as claimed in any one of claims 1 to 5, wherein the compound of formula interacts with the organic molecule in the presence of a surfactant so as to fluoresce after excitation.
7. A complex as claimed in claim 6, wherein the surfactant is selected from the group consisting of salts of long chain fatty acids or sulfonic acids.
8. A compound according to formula wherein each of R, R' and R" is a hydrogen atom, halogen atom or a straight or branched Schain Cl-2 0 alkyl, alkenyl or alkynyl group optionally substituted with one or more halogen, hydroxy and/or oxo groups; rings A, B and C are optionally substituted with one or more halogen atoms; and rings A, B and C optionally include one or more double bonds; c with the proviso that: R#-C(OH)CHC(O)(CH) 6 CH(Et)(Me) when R'=-CH 2 0H, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a; (ii) R -C(OH)CHC(O)(CH) 6 CH(Et)(Me) when R'=Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a; (iii) R#-C(OH)CHC(O)(CH) 6 CH(Et)(Me) when R'=Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and and C6; (iv) R#-C(O)(CH) 4 Me when R'=n-propyl, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; R -C(O)(CH) 6 Me when R'=n-propyl, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (vi) Rt-C(O)(CH) 5 Me when 2 Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (vii) R -C(O)(CH) 6 Me when 2 Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (viii) R -(CH) 2 C(Me)CHC(Me)(Et), when R"=Me, C4=C1, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and and C6; -26- (ix) R -(CH) 2 C(Me)CHC(Me)(Et), when R'=-Ac R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; R#-(CH) 2 C(Me)CH-i-propyl when R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; S(xi) R -C(O)(CH) 4 Me when 2 Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; 0and ring C includes a double bond between C8 and C8a and C5 and C6; (xii) R#-C(O)(CH) 4 Me when R'=-n-propyl, R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and and C6; (xiii) R#-C(O)(CH) 4 Me when R'=-n-propyl, R"=Me, rings A, B and C do not include double bonds. (xiv) R -C(O)(CH) 6 Me when R'=-C(CH) 2 Me, R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and and C6; (xv) R -C(O)(CH) 4 Me when R'=-C(CH) 2 R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8 and C4a and C5 and C6; (xvi) R -C(O)(CH) 4 Me when 2 Me, R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and and C6; (xvii) R#-C(O)(CH 2 4 Me when R'=-n-propyl, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xviii) R#-C(O)(CH 2 6 Me when R'=-n-propyl, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xix) R -C(O)(CH2) 5 Me when 2 Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; -27- S(xx) R -C(O)(CH 2 6 Me when 2 Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xxi) R*-Ac when 2 C(Me)CHCH(Me)(Et), R"=Me, C4=C1, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and N C5 and C6; (xxii) R-Ac when 2 C(Me)CHCH(Me)(Et), R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xxiii) R -Ac when 2 C(Me)CH-i-propyl, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xxiv) R -C(O)(CH 2 4 Me when 2 Me, R"=Me, ring A includes a double bond between C3 and C3a; ring B includes a double bond between C4 and C4a; and ring C includes a double bond between C8 and C8a and C5 and C6; (xxv) R -C(O)(CH 2 4 Me when R'=-n-propyl, R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and and C6; (xxvi) R#-C(O)(CH 2 4 Me when R'=-n-propyl, R"=Me, rings A, B and C do not include double bonds. (xxvii) R -C(O)(CH 2 6 Me when 2 Me, R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and and C6; (xxviii) R#-C(O)(CH 2 4 Me when R'=-C(CH 2 R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6; (xxix) R#-C(O)(CH 2 4 Me when 2 Me, R"=Me, ring A does not include a double bond; and rings B and C include double bonds between C8a and C4a and C5 and C6, including tautomers thereof.
9. A compound as claimed in claim 8 according to the formula (Ia): -28- 0 R" O 8 09 O _6 3R' R 4 (la)
10. A compound as claimed in claim 9 having the stereochemistry as depicted in formula (Ib): O SR" 29 O R 4 5 R' (Ib)
11. A compound according to formula (Ic) wherein R is C(OH)CHC(0)(CH) 6 CH 3 R' is -CH20H and R" is Me being the compound 5,6- dihydro-3-[(1Z, 4E, 6E, 8E)-l-hydroxy-3-oxo-l,4,6,8-decatetraenyl]-6-hydroxymethyl- 9a-methyl-2H-furo [3,2-g][2]benzopyran-2-9(9aH)-dione according to formula (Ic), including tautomers thereof: 0 0 OH H (Ic)
12. A compound according to any one of claims 8 to 11, wherein the compound is capable of interacting with a nitrogen containing organic molecule so as to fluoresce after excitation.
13. A complex according to any one of claims 1 to 7 or a compound as claimed in any one of claims 8 to 12, wherein the compound when interacting with a nitrogen containing organic molecule, emits fluorescence after excitation at ultraviolet to blue wavelength. -29- Fq
14. A complex as claimed in any one of claims 1 to 7 or a compound as claimed in any one of claims 8 to 12, wherein the compound when interacting with a nitrogen containing organic molecule, emits fluorescence when excited by light in the range 300- 560nm.
15. A complex or a compound as claimed in claim 14, wherein the organic molecule is a protein and the compound when interacting with the protein emits fluorescence after t excitation at 307 nm.
16. A complex or a compound as claimed in claim 14, wherein compound emits fluorescence when excited by light at about 400 nm, about 488 nm and about 514 nm.
17. A complex or a compound as claimed in claim 16, wherein compound emits fluorescence at about 600 nm after excitation at 488 nm.
18. A composition including a complex or a compound as claimed in any one of claims 1 to 17, an analytically acceptable carrier and optionally, a flurochrome.
19. A process for the preparation of a compound as claimed in any one of claims 8 to 12 comprising culturing a fungal species under conditions such that the fungal species produces the compound, and separating the compound from the culture.
Use of a compound according to formula 0 R" 8 9 0 A B C 6 R' R3 (I) wherein: each of R, R' and R" is a hydrogen atom, halogen atom or a straight or branched chain CI- 20 alkyl, alkenyl or alkynyl group optionally substituted with one or more halogen, hydroxy and/or oxo group; rings A, B and C optionally include one or more double bonds; rings B and C are optionally substituted with one or more halogen atoms, including tautomers of formula or a compound of formula including tautomers thereof: Sor a compound having the stereochemistry as depicted in formula including OI R 4 5 R O (Ia) O or a compound having the stereochemistry as depicted in formula including 1 5 tautomers thereof: R" 9 R 4 5 mR (Ib) or a compound of formula (Ia) or (Ib) wherein R is a straight or branched chain conjugated alkenyl group optionally substituted with hydroxy and oxo groups; R' is a straight or branched chain Cl.-20 alkyl group optionally substituted with a hydroxy group and R" is a straight or branched chain Ci-20 alkyl group, including tautomers thereof, or a compound according to any one of claims 8 to 12, as a fluorescent dye or marker after interaction with a nitrogen containing organic molecule.
21. Use as in claim 20, in a technique for staining, labelling and/or detecting organic molecules.
22. Use of a compound according to formula -31 wherein: each of R, R' and R" is a hydrogen atom, halogen atom or a straight or branched chain C 1 20 alkyl, alkenyl or alkynyl group optionally substituted with one or more halogen, hydroxy and/or oxo group; rings A, B and C optionally include one or more double bonds; rings B and C are optionally substituted with one or more halogen atoms, including tautomers of formula or a compound of formula including tautomers thereof: 4 (la) or a compound having the stereochemistry as depicted in formula including tautomers thereof: or a compound of formula (Ia) or (Ib) wherein R is a straight or branched chain C.- 20 conjugated alkenyl group optionally substituted with hydroxy and oxo groups; R' is a straight or branched chain C_- 20 alkyl group optionally substituted with a hydroxy group and R" is a straight or branched chain Cl- 20 alkyl group, including tautomers thereof, or a compound according to any one of claims 8 to 12, for the formation of a complex with an organic molecule, wherein the organic molecule is a nitrogen containing molecule and the complex is capable of fluorescing upon excitation. -32-
23. A method for fluorescently labelling a nitrogen containing organic molecule, Scomprising causing a compound according to formula O 0 R" O 2 A B C 0 6 6 3 SR 4 (I) 5 wherein: each of R, R' and R" is a hydrogen atom, halogen atom or a straight or branched chain C.- 20 alkyl, alkenyl or alkynyl group optionally substituted with one or more halogen, hydroxy and/or oxo group; rings A, B and C optionally include one or more double bonds; rings B and C are optionally substituted with one or more halogen atoms, including tautomers of formula or a compound of formula including tautomers thereof: O R" 0 28 3 6 R 4 R' (Ia) or a compound having the stereochemistry as depicted in formula including tautomers thereof: -33 Sor a compound of formula (Ia) or (Ib) wherein R is a straight or branched chain CI- 20 conjugated alkenyl group optionally substituted with hydroxy and oxo groups; R' is a straight or branched chain CI- 20 alkyl group optionally substituted with a hydroxy group and R" is a straight or branched chain CI- 20 alkyl group, including tautomers thereof, or a compound according to any one of claims 8 to 12, to bind to the nitrogen containing organic molecule in a manner such that the organic molecule is fluorescently labelled N with the compound.
24. A complex, compound, composition, method or use as claimed in any one of claims 1 to 23, wherein the organic molecule is a protein, peptide, sugar, nucleic acid, cell surface molecule or detergent, or is included in an antibody or a cell.
A complex, compound, composition, method or use as claimed in claim 24 wherein the compound is bound to the organic molecule through a linking moiety.
26. A method of detecting a nitrogen containing organic molecule in a sample including the organic molecule, the method comprising labelling the organic molecule according to the method of claim 23, and detecting the organic molecule in the sample by monitoring or detecting its fluorescence.
27. A method as claimed in claim 26, wherein the labelled organic molecule is detected when the sample is exposed to light from a wide range of wavelengths, preferably wavelengths in the range of 300-560 nm, more preferably ultraviolet to blue wavelengths.
28. A method as claimed in claim 26 or claim 27, wherein the monitoring or detecting of the fluorescence of the labelled-organic molecule is by transillumination, spectroscopy, microscopy or cytometry.
29. A composition including: a compound according to formula (I) -34- 0 0 9 2A B C0 6 3 R 4. Rv 0 wherein: each of R, R' and R" is a hydrogen atom, halogen atom or a straight or branched chain Cl- 20 alkyl, alkenyl or alkynyl group optionally substituted with one or more halogen, hydroxy and/or oxo group; rings A, B and C optionally include one or more double bonds; rings B and C are optionally substituted with one or more halogen atoms, including tautomers of formula and (ii) an organic molecule wherein the organic molecule is a nitrogen containing molecule and wherein the compound interacts with the organic molecule so as to fluoresce after excitation. DATED this 10 th day of July 2006 Shelston IP Attorneys for: Fluorotechnics Pty Limited
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ7117 | 2000-04-26 | ||
| AUPQ7117A AUPQ711700A0 (en) | 2000-04-26 | 2000-04-26 | Fluorescent compounds |
| PCT/AU2001/000472 WO2001081351A1 (en) | 2000-04-26 | 2001-04-26 | Fluorescent compounds |
| AU5203201A AU5203201A (en) | 2000-04-26 | 2001-04-26 | Fluorescent compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001252032A1 AU2001252032A1 (en) | 2002-01-24 |
| AU2001252032B2 true AU2001252032B2 (en) | 2006-08-03 |
Family
ID=25629488
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU5203201A Pending AU5203201A (en) | 2000-04-26 | 2001-04-26 | Fluorescent compounds |
| AU2001252032A Ceased AU2001252032B2 (en) | 2000-04-26 | 2001-04-26 | Fluorescent compounds |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU5203201A Pending AU5203201A (en) | 2000-04-26 | 2001-04-26 | Fluorescent compounds |
Country Status (1)
| Country | Link |
|---|---|
| AU (2) | AU5203201A (en) |
-
2001
- 2001-04-26 AU AU5203201A patent/AU5203201A/en active Pending
- 2001-04-26 AU AU2001252032A patent/AU2001252032B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU5203201A (en) | 2001-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8114963B2 (en) | Fluorescent compounds | |
| Bax et al. | Structure elucidation of the antibiotic desertomycin through the use of new two-dimensional NMR techniques | |
| Prinsep et al. | Tolyporphin, a novel multidrug resistance reversing agent from the blue-green alga Tolypothrix nodosa | |
| EP1732935B1 (en) | Lanthanide chelates and use thereof in bioanalysis | |
| CN108047060B (en) | Pyrene derivative fluorescent probe molecule for identifying and detecting formaldehyde and preparation method and application thereof | |
| Wei et al. | Engineering a lipid droplet targeting fluorescent probe with a large Stokes shift through ester substituent rotation for in vivo tumor imaging | |
| Cao et al. | A “turn-on” fluorescent probe for the detection of Cu 2+ in living cells based on a signaling mechanism of N [double bond, length as m-dash] N isomerization | |
| He et al. | Fluorogenic supramolecular complexes formed between pyrenyl-β-cyclodextrin and glyco-rhodamine for the selective detection of lectins | |
| Pan et al. | A novel dual channel fluorescent probe for Ca2+ and Zn2+ based on a coumarin Schiff base | |
| EP1273584B1 (en) | 2- or 4-Chromenyliden based merocyanines and use thereof | |
| Feng et al. | Turn-on fluorescent probes that can light up endogenous RNA in nucleoli and cytoplasm of living cells under a two-photon microscope | |
| AU2001252032B2 (en) | Fluorescent compounds | |
| CN108484619A (en) | A kind of rhodamine base Fe3+Fluorescence probe and preparation method thereof | |
| CN112079860B (en) | Fluorodipyrrole fluorescent probe, preparation method and application thereof in viscosity detection | |
| HK1055742B (en) | Fluorescent compounds | |
| AU2001252032A1 (en) | Fluorescent compounds | |
| Zhang et al. | Benzenesulfonamidoquinolino‐β‐cyclodextrin as a Cell‐Impermeable Fluorescent Sensor for Zn2+ | |
| CN108947935B (en) | Azine hydrazine compound and preparation method and application thereof | |
| CN113135879A (en) | Near-infrared fluorescent dye and preparation method and application thereof | |
| CN110452940A (en) | A method for separating and extracting secondary metabolites of streptomyces | |
| CN110194900A (en) | A kind of fluorescent dye and preparation method thereof emitting near infrared light | |
| CN112557354B (en) | Use of a class of benzonaphthyridine compounds with fluorescent properties | |
| Ding et al. | Diaminomaleonitrile-functionalised schiff bases: synthesis, solvatochromism, and lysosome-specific imaging | |
| CN113563360A (en) | A kind of amphiphilic fluorescent dye and its synthesis method and application | |
| Shkirdova et al. | Synthesis of β-Octaethylporphyrin Conjugates with Nitrogen and Sulfur Containing Heterocycles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |